PRA Health joins with clinical research network to improve vaccine studies

Seeking to accelerate the process of getting new vaccines to market, PRA Health Sciences ($PRAH) partnered with the Alliance for Multispecialty Research (AMR) to look for ways to help vaccine studies run more efficiently and effectively. The deal joins a leading contract research organization and a clinical research network, allowing the two "to make significant strides in implementing efficient solutions to smarter vaccine development," AMR CEO Brenda Atchison said in a statement. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.